-
The New England Journal of Medicine Oct 1991
Review
Topics: Cross Infection; Humans; Peptic Ulcer; Pneumonia; Sucralfate
PubMed: 1886624
DOI: 10.1056/NEJM199110033251407 -
Dermatologic Therapy Apr 2022Sucralfate is an aluminum salt of sucrose octasulfate, generally considered safe in terms of adverse effects. Systemic sucralfate is FDA-approved for the treatment of... (Review)
Review
Sucralfate is an aluminum salt of sucrose octasulfate, generally considered safe in terms of adverse effects. Systemic sucralfate is FDA-approved for the treatment of duodenal ulcers. Since 1991, topical sucralfate has been used in various mucocutaneous conditions, but it is not approved by the FDA yet. In this systematic review, the online databases were searched with appropriate keywords, and the papers were screened by the authors. After screening steps, the relevant articles were selected according to the inclusions and exclusions criteria. Finally, the full texts of 18 articles were included for final evaluations. In conclusion, topical sucralfate has some clinical benefit in several mucocutaneous conditions, including mucocutaneous inflammatory conditions (e.g., post-radiotherapy reaction, diaper dermatitis, keratoconjunctivitis sicca, etc.), mucocutaneous infectious disorders (e.g., peristomal wound reaction/infection); ulcers; burns, and also pain relief.
Topics: Burns; Humans; Sucralfate; Ulcer
PubMed: 35080090
DOI: 10.1111/dth.15334 -
Scandinavian Journal of... 1991The safety of sucralfate in terms of aluminium absorption, excretion, tissue accumulation, and toxicity is discussed, with special reference to the small amount of... (Review)
Review
The safety of sucralfate in terms of aluminium absorption, excretion, tissue accumulation, and toxicity is discussed, with special reference to the small amount of aluminium absorbed, its ready excretion by the normal kidney, and the hazard of toxicity in patients with advanced renal failure. The various manifestations of aluminium toxicity are described, and the notion that Alzheimer's disease should be included in this category is refuted. The clinical relevance of possible intraluminal binding and drug-drug interactions in patients receiving sucralfate therapy is also considered. Evidence is presented to show that sucralfate reduces the hyperphosphataemia in chronic uraemia, albeit at the risk of raised blood aluminium levels, but has no measurable effect on normal phosphate levels in patients with good renal function. The bioavailability of phenytoin, fluoroquinolone antibiotics, and H2-receptor blockers may be impaired by concomitant dosing with sucralfate, but normal kinetics are restored by administering the drug 2 h before sucralfate.
Topics: Biological Availability; Drug Interactions; Humans; Kidney Failure, Chronic; Sucralfate
PubMed: 1957123
DOI: No ID Found -
Journal of Critical Care Aug 2017To determine the impact of using sucralfate versus H2RAs for SUP on patient important outcomes. (Meta-Analysis)
Meta-Analysis Review
Sucralfate versus histamine 2 receptor antagonists for stress ulcer prophylaxis in adult critically ill patients: A meta-analysis and trial sequential analysis of randomized trials.
PURPOSE
To determine the impact of using sucralfate versus H2RAs for SUP on patient important outcomes.
MATERIALS AND METHODS
We searched CENTRAL, MEDLINE, EMBASE, ACPJC, clinical trials registries, and conference proceedings through June 2016 for randomized controlled trials (RCTs) comparing sucralfate to H2RAs for SUP in adult critically ill patients.
RESULTS
21 RCTs enrolling 3121 patients met inclusion criteria. There was no significant difference between sucralfate compared to H2RAs in the risk of clinically important GI bleeding (risk ratio [RR] 1.19; 95% CI [confidence interval] 0.79, 1.80; P=0.42; I=0%; low quality evidence). However, there was a statistically significant lower risk of ICU acquired pneumonia with sucralfate compared to H2RAs (RR 0.84; 95% CI 0.72, 0.98; P=0.03; I=0%; moderate quality evidence). Sucralfate did not significantly affect the risk of death (RR 0.95; 95% CI 0.82, 1.10; P=0.51; I=0%; high quality evidence), or duration of ICU stay in days (mean difference-0.39; 95% CI [-1.12, 0.34]; P=0.29; I=0%; moderate quality evidence). Trial sequential analysis adjusted estimates were consistent with conventional estimates.
CONCLUSION
Moderate quality evidence suggests that sucralfate reduced ICU acquired pneumonia compared to H2RAs in adult critically ill patients, with no significant impact on GI bleeding or death.
Topics: Adult; Anti-Ulcer Agents; Critical Illness; Histamine H2 Antagonists; Humans; Pneumonia; Randomized Controlled Trials as Topic; Stomach Ulcer; Sucralfate
PubMed: 28315586
DOI: 10.1016/j.jcrc.2017.03.005 -
JPMA. the Journal of the Pakistan... May 1992
Topics: Humans; Peptic Ulcer; Sucralfate
PubMed: 1507384
DOI: No ID Found -
Nihon Rinsho. Japanese Journal of... Feb 2002
Review
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Sucralfate; Treatment Outcome; Urease
PubMed: 11979871
DOI: No ID Found -
The American Journal of Medicine Jun 1989
Review
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Gastritis; Humans; Sucralfate
PubMed: 2660560
DOI: 10.1016/0002-9343(89)90161-7 -
The New England Journal of Medicine Mar 1992
Topics: Biological Availability; Drug Interactions; Humans; Sucralfate; Theophylline
PubMed: 1538732
DOI: 10.1056/NEJM199203193261214 -
Journal of Veterinary Internal Medicine Nov 2018The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of...
The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of inflammatory, erosive, and ultimately ulcerative lesions. This report offers a consensus opinion on the rational administration of GI protectants to dogs and cats, with an emphasis on proton pump inhibitors (PPIs), histamine type-2 receptor antagonists (H RAs), misoprostol, and sucralfate. These medications decrease gastric acidity or promote mucosal protective mechanisms, transforming the management of dyspepsia, peptic ulceration, and gastroesophageal reflux disease. In contrast to guidelines that have been established in people for the optimal treatment of gastroduodenal ulcers and gastroesophageal reflux disease, effective clinical dosages of antisecretory drugs have not been well established in the dog and cat to date. Similar to the situation in human medicine, practice of inappropriate prescription of acid suppressants is also commonplace in veterinary medicine. This report challenges the dogma and clinical practice of administering GI protectants for the routine management of gastritis, pancreatitis, hepatic disease, and renal disease in dogs and cats lacking additional risk factors for ulceration or concerns for GI bleeding. Judicious use of acid suppressants is warranted considering recent studies that have documented adverse effects of long-term supplementation of PPIs in people and animals.
Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Gastrointestinal Agents; Gastrointestinal Diseases; Misoprostol; Proton Pump Inhibitors; Sucralfate
PubMed: 30378711
DOI: 10.1111/jvim.15337 -
Scandinavian Journal of... 1995Chemotherapy and radiotherapy of different malignancies may be complicated by a variety of side effects, some of which may be related mucosal damage. (Review)
Review
BACKGROUND
Chemotherapy and radiotherapy of different malignancies may be complicated by a variety of side effects, some of which may be related mucosal damage.
RESULTS
There is increasing evidence that sucralfate reduces the severity of radiation-induced mucositis in the head and neck, esophagus, and the lower gastrointestinal tract. Sucralfate also seems to protect the skin during radiotherapy and to reduce chemotherapy-induced mucositis.
CONCLUSION
Further studies could be of interest to define the clinical significance of sucralfate in reducing the mucosal damage and increasing quality of life during an following cancer therapy.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Humans; Intestinal Diseases; Intestinal Mucosa; Neoplasms; Radiotherapy; Sucralfate
PubMed: 8578206
DOI: 10.3109/00365529509090270